🇺🇸 FDA

Drug profile · INN

tradipitant

NEREUS

approved
US status
approved
Patents linked
6
News articles
0

Quick answer

tradipitant (NEREUS) is an FDA-listed pharmaceutical active ingredient. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN tradipitant
Brand NEREUS
Route ORAL
Formulation CAPSULE
Originator Vanda Pharmaceuticals Netherlands B.V.

Related patents

Search patents →

  1. US 12318375

    Method of treatment with tradipitant

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11549147

    Treatment of atopic dermatitis with tradipitant

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11324735

    Method of treatment with tradipitant

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10821099

    Use of tradipitant in motion sickness

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10772880

    Method of treatment with tradipitant

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10463655

    Method of treatment with tradipitant

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is tradipitant?

tradipitant (NEREUS) is an FDA-listed pharmaceutical active ingredient. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for tradipitant?

NEREUS is a marketed brand name for tradipitant. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tradipitant?

tradipitant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.